Stock comparison
Boston Scientific
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BSX
Boston Scientific
Market cap
$85.88B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Fit scores by strategy
| Strategy | BSX | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 63C | 65C | GMAB |
| Benjamin Graham | 69B | 64C | BSX |
| Philip Fisher | 70C | 48D | BSX |
| Peter Lynch | 58C | 25F | BSX |
| Joel Greenblatt | 44D | 76B | GMAB |
| Charlie Munger | 54D | 68C | GMAB |
| Terry Smith | 59D | 71C | GMAB |
Side-by-side metrics
| Metric | BSX | GMAB |
|---|---|---|
| Market cap | $85.88B | $16.5B |
| P/E (TTM) | 22.0x | 6.2x |
| EV/EBIT | 22.1x | 12.0x |
| ROIC (TTM) | 9.9% | 43.78% |
| Gross margin | 70.41% | 93.88% |
| Net margin | 17.24% | 18.23% |
| Revenue CAGR 5y | 13.99% | -18.45% |
| EPS CAGR 5y | 29.71% | -23.48% |
| Debt / Equity | 0.4x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BSX leads on
- EPS CAGR 5y29.71%vs -23.48%+179%
- Revenue CAGR 5y13.99%vs -18.45%+176%
- Market cap$85.88Bvs $16.5B+81%
GMAB leads on
- Debt / Equity0.1xvs 0.4x+83%
- ROIC (TTM)43.78%vs 9.9%+77%
- P/E (TTM)6.2xvs 22.0x+72%
- EV/EBIT12.0xvs 22.1x+46%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.